Generic Medicine Info
Indications and Dosage
Adult: 25-200 mg daily.

Adult: 25-600 mg daily in 2 or 3 divided doses with larger doses taken at night.
Elderly: Dose reduction may be necessary.
Coma, CNS depression and phaeochromocytoma.
Special Precautions
Renal and hepatic impairment, CV disease, Parkinson's disease, epilepsy, depression, myasthenia gravis, prostatic hypertrophy, elderly, history of angle-closure glaucoma, severe respiratory disease, blood dyscrasias or history of jaundice. Photosensitisation may occur. May affect performance of skilled tasks. Gradual withdrawal after long-term therapy and monitor closely to avoid risk of acute withdrawal syndromes or rapid relapse. Pregnancy, lactation.
Adverse Reactions
Parkinsonian symptoms, dystonia, akathisia, tardive dyskinesia. Interference with temp regulation. CNS effects, GI disturbances, nasal congestion, antimuscarinic symptoms, CV symptoms, ECG changes, endocrine effects, blood dyscrasias, photosensitisation, contact sensitisation and rashes, jaundice, corneal and lens opacities, purplish pigmentation of the skin, cornea, conjunctiva and retina.
Potentially Fatal: Neuroleptic malignant syndrome.
Drug Interactions
Increased risk of extrapyramidal adverse effects when used with SSRIs. May cause neuroleptic malignant syndrome or hyperpyrexia when used with chlorpromazine, levomepromazine or trifluoperazine.
Description: Cyamemazine is a phenothiazine with general properties similar to those of chlorpromazine. It is used in the management of a variety of psychiatric disorders including anxiety disorders and aggressive behaviour.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cyamemazine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in